People

Bill Anderson was named CEO of Genentech, a member of the Roche Group, earlier this year after 10 years in various leadership positions at the company. He replaces Ian T. Clark, who retired at the end of 2016 after 14 years of service. Anderson, who is also the head of North American commercial operations, most recently served as the head of Global Product Strategy.

Eric Fearon, MD, PhD, was named director of the University of Michigan Comprehensive Cancer Center in Ann Arbor last fall. He succeeds Theodore Lawrence, MD, PhD, who will continue to chair the university's department of radiation oncology.

Fearon is a nationally recognized investigator in cancer genetics. His research has led to a greater understanding of gene defects that cause colon and rectal cancers to spread and develop. In addition to serving as division chief for Molecular Medicine and Genetics, he assumed the role of deputy director of the cancer center in 2005.

After a 2-year stint as chairman and CEO of the Massachusetts General Hospital (MGH) Physicians Organization in Boston and a member of the MGH Board of Directors, Thomas J. Lynch Jr., MD, was named chief scientific officer at Bristol-Myers Squibb. Prior to moving to MGH, Lynch directed the Yale Cancer Center in New Haven, CT, from 2009–2015. He also served as physician-in-chief of Yale New Haven Health Smilow Cancer Hospital.

While at MGH earlier in his career, Lynch was part of the team credited with discovering that certain genetic mutations in patients with lung cancer caused therapies to work in some people but not others.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.